BioVector® RIL-175 小鼠肝细胞癌细胞系Mouse Hepatocellular Carcinoma Cell Line BioVector NTCC质粒载体菌株细胞蛋白抗体基因保藏中心

BioVector® RIL-175 小鼠肝细胞癌细胞系 / Mouse Hepatocellular Carcinoma Cell Line 数据说明书

产品名称: BioVector® RIL175 细胞
同义词: BioVector® RIL-175
中文名称: BioVector® RIL175 小鼠肝细胞癌细胞系
英文名称: BioVector® RIL175 Mouse Hepatocellular Carcinoma Cell Line
产品类别: 肿瘤细胞系；肝癌研究模型
物种来源: 小鼠 (Mus musculus)，C57BL/6 品系
组织来源: 胚胎肝组织
细胞类型: 肝细胞癌细胞
疾病: 肝细胞癌 (Hepatocellular carcinoma, HCC)
细胞来源: 源自 p53 基因敲除小鼠胚胎肝细胞，通过转导携带 p.Gly12Val 突变的 HRAS 癌基因转化建立
基因特征:

1. Trp53 敲除: 采用基因敲除小鼠技术构建，Trp53 基因功能缺失

2. HRAS 突变: 稳定整合 HRAS 基因并表达 p.Gly12Val 突变型 HRAS 蛋白

3. 致瘤性: 在 C57BL/6 同系小鼠中具有高度致瘤性，可用于建立原位肝癌模型
   形态特性: 上皮细胞样
   生长特性: 贴壁生长
   特性特征:

4. 免疫活性模型: 来源于 C57BL/6 小鼠，可在免疫健全的同系小鼠中建立肿瘤模型，适用于肿瘤免疫学研究

5. 原位成瘤: 通过原位注射可建立稳定的肝细胞癌模型，模拟人肝癌的肿瘤微环境

6. 免疫治疗研究: 广泛用于抗 PD-1 抗体、腺苷 A2a 受体抑制剂等免疫检查点抑制剂的疗效评估

7. 耐药模型: 衍生出索拉非尼耐药亚系 BioVector® RIL175-R，用于肝癌耐药机制研究

8. 基因编辑: 已建立 TRPML1 基因敲除亚系，用于研究溶酶体功能与线粒体代谢的关系

9. 联合治疗: 常用于评估联合治疗策略，如抗 PD-1 与抗 CXCR4 联合、A2aR 抑制剂与免疫治疗联合等
   研究应用:

10. 肝细胞癌发病机制研究

11. 肿瘤免疫治疗疗效评估

12. 免疫检查点抑制剂联合治疗策略开发

13. 肝癌耐药机制研究

14. 肿瘤微环境与免疫细胞相互作用研究

15. 线粒体功能与肿瘤代谢研究
    培养基: BioVector® RIL175 细胞专用完全培养基（推荐基础成分：DMEM 高糖培养基，添加 20% 胎牛血清、1 mM 丙酮酸钠和 1% 青霉素-链霉素）
    培养条件: 气相：95% 空气，5% 二氧化碳；温度：37°C
    传代方法: 当细胞融合度达到 80-90% 时，推荐使用 BioVector® 专用传代试剂（如 0.25% 胰蛋白酶-EDTA）进行消化，按 1:3 至 1:6 比例进行传代，每周传代 2-3 次
    冻存液: BioVector® 细胞冻存液（推荐配方：90% 胎牛血清 + 10% DMSO）
    质量控制: 支原体检测：阴性；无菌检测：阴性；STR 分型：已验证；致瘤性验证：阳性
    储存与运输: 液氮或干冰运输与保存
    生物安全等级: 1（需在二级生物安全柜内操作）
    相关细胞系: BioVector® RIL175-R（索拉非尼耐药亚系）；BioVector® RIL175 TRPML1 KO（TRPML1 基因敲除亚系）
    仅供科研使用

English:
BioVector® RIL175 Mouse Hepatocellular Carcinoma Cell Line Datasheet

Product Name: BioVector® RIL175 Cells
Synonyms: BioVector® RIL-175
Chinese Name: BioVector® RIL175 小鼠肝细胞癌细胞系
English Name: BioVector® RIL175 Mouse Hepatocellular Carcinoma Cell Line
Product Category: Cancer Cell Line; Liver Cancer Research Model
Species of Origin: Mouse (Mus musculus), C57BL/6 strain
Tissue of Origin: Embryonic liver tissue
Cell Type: Hepatocellular carcinoma cells
Disease: Hepatocellular carcinoma (HCC)
Derivation: Derived from p53 knockout mouse embryonic hepatocytes, transformed by transduction with HRAS oncogene carrying p.Gly12Val mutation
Genetic Features:

1. Trp53 Knockout: Trp53 gene knockout via KO mouse technology, resulting in loss of function

2. HRAS Mutation: Stably integrated HRAS gene expressing p.Gly12Val mutant HRAS protein

3. Tumorigenicity: Highly tumorigenic in syngeneic C57BL/6 mice, suitable for establishing orthotopic liver cancer models
   Morphology: Epithelial-like
   Growth Characteristics: Adherent
   Characteristics:

4. Immunocompetent Model: Derived from C57BL/6 mice, enables tumor model establishment in immunocompetent syngeneic mice, suitable for tumor immunology research

5. Orthotopic Tumor Formation: Stable hepatocellular carcinoma model established via orthotopic injection, recapitulating the tumor microenvironment of human HCC

6. Immunotherapy Research: Widely used for efficacy evaluation of immune checkpoint inhibitors such as anti-PD-1 antibodies and adenosine A2a receptor inhibitors

7. Drug Resistance Model: Sorafenib-resistant subline BioVector® RIL175-R available for HCC resistance mechanism studies

8. Gene Editing: TRPML1 knockout subline established for investigating lysosomal function and mitochondrial metabolism

9. Combination Therapy: Commonly used for evaluating combination therapy strategies, including anti-PD-1 with anti-CXCR4, A2aR inhibitors with immunotherapy, etc.
   Research Applications:

10. Hepatocellular carcinoma pathogenesis studies

11. Tumor immunotherapy efficacy evaluation

12. Immune checkpoint inhibitor combination therapy strategy development

13. HCC drug resistance mechanism studies

14. Tumor microenvironment and immune cell interaction studies

15. Mitochondrial function and tumor metabolism studies
    Culture Medium: BioVector® Complete Medium for RIL175 Cells (Recommended composition: DMEM high glucose medium supplemented with 20% fetal bovine serum, 1 mM sodium pyruvate, and 1% penicillin-streptomycin)
    Culture Conditions: Atmosphere: 95% air, 5% CO₂; Temperature: 37°C
    Subculturing Method: When cells reach 80-90% confluence, recommended to use BioVector® Subculture Reagent (e.g., 0.25% Trypsin-EDTA). Subculture at a split ratio of 1:3 to 1:6, 2-3 times per week
    Freeze Medium: BioVector® Cell Freeze Medium (Recommended composition: 90% FBS + 10% DMSO)
    Quality Control: Mycoplasma: Negative; Sterility: Negative; STR Profiling: Authenticated; Tumorigenicity Validation: Positive
    Storage and Shipment: Stored and shipped in liquid nitrogen or on dry ice
    Biosafety Level: 1 (Operate in a Class II biological safety cabinet)
    Related Cell Lines: BioVector® RIL175-R (Sorafenib-resistant subline); BioVector® RIL175 TRPML1 KO (TRPML1 knockout subline)
    For Research Use Only

BioVector NTCC质粒载体菌株细胞蛋白抗体基因保藏中心

电话:400-800-2947

工作QQ/微信同号:1843439339

网址http://www.biovector.net